Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Dacomitinib in squamous cell carcinoma of the penis
2012-003590-25Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in penile squamous cell carcinoma (PSCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Response rate. Started Nov 2012; status: terminated.
02
Drugs
dacomitinib
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on 2012-003590-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003590-25.